Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Mutations in cancer cells frequently result in cell cycle alterations that lead to unrestricted
growth compared to normal cells. Considering this phenomenon, many drugs have been …
growth compared to normal cells. Considering this phenomenon, many drugs have been …
Vinflunine for the treatment of breast cancer
C Gourmelon, H Bourien, P Augereau… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Breast cancer is the most frequently diagnosed cancer and the highest cause of
cancer mortality in females worldwide. The development of drugs improving overall survival …
cancer mortality in females worldwide. The development of drugs improving overall survival …
Effects of fucoidan and chemotherapeutic agent combinations on malignant and non-malignant breast cell lines
A Abudabbus, JA Badmus, S Shalaweh… - Current …, 2017 - ingentaconnect.com
Objectives: Breast cancer is a leading cause of death among women in both developed and
Third World countries. Fucoidan is a natural plant metabolite produced by brown seaweeds …
Third World countries. Fucoidan is a natural plant metabolite produced by brown seaweeds …
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
H Gerullis, C Eimer, TH Ecke, E Georgas… - Anti-cancer …, 2013 - journals.lww.com
The role of pazopanib in the second-line setting of refractory metastatic transitional cell
carcinoma of the urothelium has not been defined clearly. The aim of this phase I/II trial was …
carcinoma of the urothelium has not been defined clearly. The aim of this phase I/II trial was …
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
M Campone, N Isambert, E Bourbouloux… - Cancer chemotherapy …, 2012 - Springer
Purpose A phase I study was performed to determine the maximal tolerated dose (MTD),
recommended dose (RD), safety and efficacy of vinflunine when combined with …
recommended dose (RD), safety and efficacy of vinflunine when combined with …
New vinca alkaloids in clinical development
P Fumoleau, S Guiu - Current Breast Cancer Reports, 2013 - Springer
The most successful tubulin-targeting agents in the treatment of breast cancer are the
taxanes and the Vinca alkaloids. Vinorelbine, a vinca alkaloid derivative, has remarkable …
taxanes and the Vinca alkaloids. Vinorelbine, a vinca alkaloid derivative, has remarkable …
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer
S Chan, M Campone, A Santoro, PF Conte… - Cancer chemotherapy …, 2014 - Springer
Background Vinflunine (VFL) is a bifluorinated tubulin-targeted agent of the vinca alkaloids
class active in advanced stage breast cancer. We conducted a phase I study combining VFL …
class active in advanced stage breast cancer. We conducted a phase I study combining VFL …
Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials
A Schmitt, L Nguyen, G Zorza, P Ferré… - British journal of …, 2018 - Wiley Online Library
Aims Vinflunine is a novel tubulin‐targeted inhibitor indicated as a single agent for the
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …
The effects of various combinations of different classes of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 breast carcinoma cell line
B Abrahams - 2014 - etd.uwc.ac.za
This study investigated the effects of TKIs on the growth and proliferation of MCF-7 breast
carcinoma cells in culture. MCF-7 cells were exposed to different concentrations of TKIs …
carcinoma cells in culture. MCF-7 cells were exposed to different concentrations of TKIs …
Translational research to realize the full potential of novel agents–an opportunity for vinflunine?
AYS Yip, EYY Ong, LWC Chow - Expert Opinion on Drug Safety, 2012 - Taylor & Francis
In the past few years, innumerable novel anti-cancer agents have been developed. Some of
them have successfully entered into clinical practice while some of them have failed for …
them have successfully entered into clinical practice while some of them have failed for …